(HealthDay News) — Reporting of financial conflicts of interest (COIs) has increased over time in clinical practice guidelines and consensus statements for the treatment of common solid tumors, according to research published in the Journal of Clinical Oncology.
In an effort to examine self-reported author financial COIs, Ariadna Tibau, MD, from the Hospital de la Santa Creu i Sant Pau in Barcelona, Spain, and colleagues identified clinical practice guidelines and consensus statements for common solid cancers published between January 2003 and October 2013.
The authors also extracted data on funding sources, use of manuscript writers and endorsement of specific drugs in the article abstract. Data were included for 142 articles, of which 64% were clinical practice guidelines and 36% consensus statements.
The researchers found that from 2003 to 2013, the proportion of articles reporting financial COIs increased from 11% to 93% (P for trend <.001). Funding sources were explicitly reported in only 45% of articles, 65% of which disclosed full or partial industry sponsorship.
Thirteen percent of articles declared use of manuscript writers, but many articles did not specifically report the authors’ roles in writing the manuscript. There was a significant correlation for endorsement of specific drugs with author financial COIs (OR=7.29; P=.001), but not with industry funding (OR=0.95; P=.37).
“Despite prevalent funding of guideline development by industry, such funding is not associated with endorsement of specific drugs,” the researchers wrote.